ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,594.19
0.40%
US Tech 100
19,151.20
1.52%
다우존스 지수
41,278.58
-0.37%
Bitcoin
82,367.62
-0.58%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Vir Biotechnology Inc (VIR)

  7. Vir Biotechnology Inc (VIR) 뉴스

Vir Biotechnology Inc

Vir Biotechnology Inc (VIR)

Vidrala SA
7.375
0.035
( 0.48% )
업데이트: 23:10:01
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

VIR 뉴스

공식 뉴스 전용

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
19 11월 2024
VIR (0.48%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 11월 2024
VIR (0.48%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
07 11월 2024
VIR (0.48%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 11월 2024
VIR (0.48%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
06 11월 2024
VIR (0.48%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
05 11월 2024
VIR (0.48%)

Form 8-K - Current report
Edgar (US Regulatory)
01 11월 2024
VIR (0.48%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
04 10월 2024
VIR (0.48%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
03 10월 2024
VIR (0.48%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
03 10월 2024
VIR (0.48%)

VIR Discussion

게시물 보기
Monksdream Monksdream 3 월 전
VIR under $8
👍️0
DewDiligence DewDiligence 4 월 전
VIR reports 3Q24 results—9/30/24 cash=$1.19B:

https://www.businesswire.com/news/home/20241031806056/en
👍️0
Monksdream Monksdream 4 월 전
VIR under $10
👍️0
TheFinalCD TheFinalCD 7 월 전
$VIR PR during News Halt on Aug. 01 2024

Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers— NuntioBot (@NuntioBot) August 1, 2024

https://finviz.com/quote.ashx?t=VIR&p=d#google_vignette

Message in reply to:
VIR pares pipeline—reduces workforce 25%:

https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Reports-Second-Quarter-2024-Financial-Results-and-Announces-Strategic-Restructuring-to-Prioritize-Clinical-Stage-Pipeline-Opportunities/default.aspx

VIR has terminated its programs in flu, COVID, and T cell-based viral vectors.

VIR also announced a collaboration with SNY to develop T-cell engagers (https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Acts-on-Expanded-Strategy-of-Powering-the-Immune-System-Through-Exclusive-Worldwide-License-Agreement-with-Sanofi-for-Multiple-Potential-Best-in-Class-Clinical-Stage-T-cell-Engagers/default.aspx ), but financial terms of the collaboration were not disclosed.


2Q24 CC slides:
https://s203.q4cdn.com/628578897/files/doc_presentations/2024/Jul/Vir-Corporate-Presentation_Q2-2024.pdf
👍️0
DewDiligence DewDiligence 7 월 전
VIR pares pipeline—reduces workforce 25%:

https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Reports-Second-Quarter-2024-Financial-Results-and-Announces-Strategic-Restructuring-to-Prioritize-Clinical-Stage-Pipeline-Opportunities/default.aspx

VIR has terminated its programs in flu, COVID, and T cell-based viral vectors.

VIR also announced a collaboration with SNY to develop T-cell engagers (https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Acts-on-Expanded-Strategy-of-Powering-the-Immune-System-Through-Exclusive-Worldwide-License-Agreement-with-Sanofi-for-Multiple-Potential-Best-in-Class-Clinical-Stage-T-cell-Engagers/default.aspx ), but financial terms of the collaboration were not disclosed.


2Q24 CC slides:
https://s203.q4cdn.com/628578897/files/doc_presentations/2024/Jul/Vir-Corporate-Presentation_Q2-2024.pdf
👍️0
Monksdream Monksdream 7 월 전
VIR under $11
👍️0
Monksdream Monksdream 8 월 전
VIR under $10
👍️0
DewDiligence DewDiligence 9 월 전
VIR +18% on phase-2 HDV data at EASL:

https://finance.yahoo.com/news/tobevibart-monotherapy-combination-therapy-elebsiran-093000369.html

Note: HDV is a subset of HBV insofar as HDV resides within HBV’s capsid.
👍️0
DewDiligence DewDiligence 10 월 전
VIR 1Q24 CC transcript:

https://finance.yahoo.com/news/vir-biotechnology-inc-nasdaq-vir-170535096.html
👍️0
Monksdream Monksdream 10 월 전
VIR still reversing off the recent 52 week low
👍️0
DewDiligence DewDiligence 10 월 전
VIR reports 1Q24 results—3/31/24 cash=$1.51B(!):

https://www.businesswire.com/news/home/20240502260564/en

VIR re-iterated guidance for 2024 operating expenses of $650-680M.

CC slides:
https://investors.vir.bio/files/doc_financials/2024/q1/Vir-Corporate-Presentation_Q1-2024.pdf
👍️0
Monksdream Monksdream 10 월 전
VIR under $10
👍️0
DewDiligence DewDiligence 11 월 전
VIR adds two luminaries to BoD:

https://www.businesswire.com/news/home/20240418098064/en

The capsule bios in the PR speak for themselves.
👍️0
DewDiligence DewDiligence 1 년 전
VIR 4Q23 CC transcript:

https://finance.yahoo.com/news/q4-2023-vir-biotechnology-inc-185403667.html
👍️ 1
DewDiligence DewDiligence 1 년 전
VIR 4Q23 CC slides:

https://investors.vir.bio/files/doc_presentations/2024/02/22/Vir-Corporate-Presentation_Q4-2023.pdf
👍️0
DewDiligence DewDiligence 1 년 전
VIR reports 4Q23 results—issues 2024 expense guidance:

https://www.businesswire.com/news/home/20240222740501/en

12/31/23 cash was $1.63B, after burning $108M during 4Q23.

2024 guidance for SG&A + R&D GAAP expenses is $650-680M.

At the current share price, VIR has an enterprise value of roughly negative $200M.
👍️0
DewDiligence DewDiligence 1 년 전
VIR’s CMO left the company, which explains the exercise-and-hold transaction from January in the post I'm replying to:

https://finance.yahoo.com/news/vir-biotechnology-announces-dr-phil-213000676.html

Note: The above was issued on 2/20/24.
👍️0
DewDiligence DewDiligence 1 년 전
GSK, VIR terminate flu collaboration inked in 2021:

https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/0001706431/000162828024006346/vir-20240221.htm

This outcome is not surprising outcome insofar as the phase-2 trial of VIR-2484, the lead compound of the collaboration, was a failure ( #msg-172395320).
👍️0
DewDiligence DewDiligence 1 년 전
VIR’s CMO exercised and held ~$800K of stock yesterday:

https://www.sec.gov/Archives/edgar/data/1706431/000162828024000169/xslF345X05/wk-form4_1704311270.xml

The options in question did not expire until 2027-2028.
👍️0
DewDiligence DewDiligence 1 년 전
VIR cuts workforce 12%:

https://www.businesswire.com/news/home/20231213396441/en

It’s bizarre to see belt-tightening by a company with $1.7B of net cash (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001706431/000162828023036702/vir-20230930.htm#i4ba948c416a6412b946073491455ca74_19 ), but it’s probably the right thing to do inasmuch as the stock’s EV is deeply negative.
👍️0
harry crumb harry crumb 1 년 전
Nice move today
👍️0
DewDiligence DewDiligence 2 년 전
VIR -45% on phase-2 failure in influenza:

https://finance.yahoo.com/news/vir-biotechnology-announces-topline-data-120000102.html Vir Biotechnology…today announced that the Phase 2 PENINSULA trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. Why such a steep selloff? One reason is that VIR has tended to present itself to investors as all-powerful and all-knowing, which is perhaps a consequence of having George Scangos as (ex)CEO and having raised a huge amount of capital based on management’s reputation.
👍️0
DewDiligence DewDiligence 2 년 전
VIR starts 4-drug phase-2 HBV trial:

https://www.globenewswire.com/news-release/2023/05/11/2666740/0/en/Vir-Biotechnology-Announces-First-Patient-Dosed-in-New-Phase-2-Chronic-Hepatitis-B-Virus-Trial-Evaluating-Combinations-of-VIR-2218-VIR-3434-PEG-IFN%CE%B1-and-an-NRTI.html

The four drugs are: VIR-2218, a siRNA; VIR-3434, a mAb; PEG-IFN; and a (generic) nucleoside.

A separate phase-2 trial (VIR calls it a “subprotocol”) will test VIR-3434 and a nuke, with and without VIR-2218, in patients who are chronic inactive carriers of the HBV virus. I'm unclear as to whether this second trial is for research purposes or for an addressable commercial market.
👍️0
DewDiligence DewDiligence 2 년 전
48w VIR-2219 +peg-IFN—>31% HBs seroconverion:

https://www.globenewswire.com/news-release/2022/11/06/2549180/0/en/Vir-Biotechnology-Presents-New-Data-Evaluating-the-Potential-for-VIR-2218-and-VIR-3434-to-Achieve-a-Functional-Cure-for-Chronic-Hepatitis-B-Virus-HBV-Infection.html

The 31% figure is impressive insofar as peg-IFN by itself has a 48w seroconversion rate of only 5-10%. Of course, a 48w regimen of VIR-2219 + peg-IFN won’t be any easier to tolerate than 48w of peg-IFN monotherapy, so this regimen is still far from the ultimate answer for treating chronic HBV.

VIR has started testing the triple combination of VIR-2219 (siRNA) + VIR-3434 (mAb) + peg-IFN; initial data are expected in 2H23.
👍️0
DewDiligence DewDiligence 3 년 전
VIR EASL presentations:

https://www.globenewswire.com/news-release/2022/06/25/2469082/0/en/Vir-Biotechnology-Announces-New-Clinical-Data-From-its-Broad-Hepatitis-B-Program.html

No CC.
👍️0
DewDiligence DewDiligence 3 년 전
VIR HBV webcast slides:

https://investors.vir.bio/static-files/7ece44c3-0585-47af-81b4-2199889d6934
👍️0
DewDiligence DewDiligence 3 년 전
VIR -14% on amended Sotrovimab EUA due to Omicron BA.2 variant:

https://finance.yahoo.com/news/us-food-drug-administration-revises-200400156.html GlaxoSmithKline plc and Vir Biotechnology…today announced that the US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal antibody. The FDA has determined that, based on the totality of available evidence, including new live virus data generated by Vir, it is unlikely that the sotrovimab 500 mg dose will be effective against the Omicron BA.2 variant.

GSK and Vir are preparing a package of data in support of a higher dose of sotrovimab for the Omicron BA.2 subvariant and will be sharing these data with regulatory and health authorities around the world for discussion. This PR was issued after the close, but the market apparently got wind of the FDA decision about 3:45pm ET.
👍️0
DewDiligence DewDiligence 3 년 전
VIR 4Q21 results:

https://www.globenewswire.com/news-release/2022/02/24/2391890/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html As of December 31, 2021, excluding restricted cash, the Company had approximately $909.5 million in cash, cash equivalents, and investments. Excluding restricted cash and its equity investment in Brii Biosciences, the Company had approximately $766.4 million in cash, cash equivalents and investments.
👍️0
DewDiligence DewDiligence 3 년 전
VIR’s 2022 HBV newsflow:

https://www.globenewswire.com/news-release/2022/02/24/2391890/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html In 2022, the Company expects data readouts from multiple trials evaluating VIR-2218 and VIR-3434:

• Initial data from the first cohorts of Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial of VIR-2218 in combination with VIR-3434, are expected in the first half of 2022.

• Additional data from the Phase 2 trial of VIR-2218 in combination with PEG-IFN-alpha are expected in the first half of 2022.

• Additional data from the Phase 1 monotherapy trial of VIR-3434 are expected in the first half of 2022.

• The Company’s collaborator, Brii Biosciences, continues to lead the Phase 2 trial evaluating VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the potential treatment of chronic HBV infection. Initial data are expected in the second half of 2022. Evidently, there will not be a 2022 readout from the phase-2 trial testing combinations of VIR-2218, GILD’s GS-9688, Vemlidy (TAF), and Opdivo (#msg-167061759, #msg-160854272, #msg-167063133).
👍️0
rwwest rwwest 3 년 전
Up so far on another Biotech down day
Seems like a good omen.
👍️0
DewDiligence DewDiligence 3 년 전
VIR slide set from JPM:

https://investors.vir.bio/static-files/7ecf45fb-6918-4cf8-9a02-b8c12183ca4f
👍️0
DewDiligence DewDiligence 3 년 전
VIR/GILD start phase-2 trial testing quadruple regimen of VIR-2218; GS-9688; Opdivo; and Vemlidy (TAF) in (both nuc-suppressed and viremic) HBV patients:

https://finance.yahoo.com/news/vir-biotechnology-announces-initiation-phase-133000267.html

I’m not sure why it took almost a year for this trial to begin enrolling patients—the PR announcing the collaboration was issued on 1/12/21.

Please see #msg-160854272 for background.
👍️0
HokieHead HokieHead 3 년 전
Loaded again. After omicron news all weekend this will be the next MRNA biotech. $75+ by years end for starters imo.
👍️0
HokieHead HokieHead 3 년 전
In $46, omicron play.
👍️0
DewDiligence DewDiligence 4 년 전
VIR starts HBV_combination_trial_of_ VIR-2218 and VIR-3434:

https://finance.yahoo.com/news/vir-biotechnology-initiates-phase-2-123000780.html The multi-center, open-label Phase 2 trial is designed to evaluate the safety, tolerability and efficacy of the combination of VIR-2218 and VIR-3434 in approximately 90 adult patients (ages 18 to 65) with chronic HBV infection receiving nucleot(s)ide reverse transcriptase inhibitor therapy. Both VIR-2218 and VIR-3434 will be administered via subcutaneous injection at varying dose levels over the course of the trial for a treatment period ranging from four to 20 weeks, and a follow-up period of up to 116 weeks, depending on the dosing cohort.

…VIR-2218 is an investigational small interfering ribonucleic acid (siRNA) designed to inhibit the production of all HBV proteins (X, polymerase, S and core), which may be acting as immune tolerogens. VIR-3434 is an investigational HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes, as well as reduce the level of virions and subviral particles in the blood. It has also been Fc engineered to include the XX2 “vaccinal mutation,” allowing it to potentially function as a therapeutic T cell vaccine against HBV. See #msg-164593550, #msg-161217289, and #msg-164599741 for related info.
👍️0
DewDiligence DewDiligence 4 년 전
VIR -6% on VIR-2218 and VIR-3434 monotherapy data presented at EASL:

https://finance.yahoo.com/news/vir-biotechnology-presents-clinical-data-125000851.html

CC to discuss these data with investment community at 11am ET.
👍️0
level42 level42 4 년 전
"profound efficacy." Vir Biotechnology and GSK plan to seek emergency use authorization for their experimental COVID-19 antibody therapy after interim data from a study showed 85% reduction in hospitalization and deaths among patients.


Based on these positive results, Vir and GlaxoSmithKline intend to request Emergency Use Authorization (EUA) for VIR-7831 from the U.S. Food and Drug Administration (FDA) and other international regulators.

"We are pleased that this unique monoclonal antibody was able to bring such a profound benefit to patients," GlaxoSmithKline chief scientific officer Dr. Hal Barron said. "We look forward to the possibility of making VIR-7831 available to patients as soon as possible."
👍️0
interloper interloper 4 년 전
Too high too fast. Very typical price movement. I you think your gonna ride a rocket to the moon you better be ready when the booster fuel runs out.
👍️0
dealerschool2006 dealerschool2006 4 년 전
why is VIR coming back down???
👍️0
rtrstock rtrstock 4 년 전
Huge disappointment.

This could go back to under 20.00 pps

Should have sold at 140.00

This stock price is just based on hype, the collapse is the reality of things.

👍️0
CatBirdSeat CatBirdSeat 4 년 전
Two New Rockships Taking Off After VIR

Behold! FNMA & FMCC

Ka Ching ! Baby! $$$$
👍️0
rtrstock rtrstock 4 년 전
I Should have sold at 140.00

Now it's in a death spiral.

Robinhood shows this listing at a completely different price than ihub.
👍️0
Srhogan1984 Srhogan1984 4 년 전
Full of crap haha
👍️0
ClayTrader ClayTrader 4 년 전
* * $VIR Video Chart 01-26-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
Srhogan1984 Srhogan1984 4 년 전
Sounds like a short to me. You need a bog squeeze? Haha
👍️0
DewDiligence DewDiligence 4 년 전
Today's move is somewhat scary in the context of #msg-160142077.
👍️0
DewDiligence DewDiligence 4 년 전
VIR—(+40% undeservedly, IMO)—on_interim_phase-1_data_for VIR-3434_in_HBV:

https://www.globenewswire.com/news-release/2021/01/26/2164220/0/en/Initial-Data-from-Ongoing-Phase-1-Trial-of-VIR-3434-for-Chronic-Hepatitis-B-Virus-Infection-Demonstrates-Significant-and-Rapid-Reduction-in-Hepatitis-B-Surface-Antigen.html

The mean reduction in HBsAg (n=6) was 1.3 logs after 8 days. That’s not bad, but neither is it a knock-your-socks-off result. Monotherapy is unlikely to generate a functional cure in HBV, no matter how potent the agent may be against HBsAg.

VIR-3434 is a monoclonal antibody and is VIR’s second HBV agent in the clinic; the first is VIR-2218, an RNAi agent (#msg-155042587).
👍️0
DewDiligence DewDiligence 4 년 전
Not really. It's just a phase-2 trial, not a full-fledged partnership.
👍️0
DewDiligence DewDiligence 4 년 전
GILD, VIR collaborate on phase-2 HBV trial:

https://www.businesswire.com/news/home/20210112005578/en The companies plan to initiate a Phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naïve people living with HBV. The multi-arm trial will evaluate different combinations of selgantolimod, Gilead’s investigational TLR-8 agonist; VIR-2218, Vir’s investigational small interfering ribonucleic acid (siRNA); and a commercially-sourced, marketed PD-1 antagonist. People in the trial with HBV treatment experience may also receive Gilead’s Vemlidy (tenofovir alafenamide fumarate, TAF). The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum.

Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial. I.e., no cash is changing hands between the two companies.
👍️0
Srhogan1984 Srhogan1984 4 년 전
Huge news!
👍️0

최근 히스토리

NASDAQ
VIR
Vir Biotechnology
BIT
P20EM8
NLBNPIT20EM8 20351221 39...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지